Marie Florescu
Montreal, QC H3T1J4, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives.
Journal: Current oncology (Toronto, Ont.)
Published: June 21, 2026
A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas.
Journal: Current oncology (Toronto, Ont.)
Published: July 30, 2025
Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report.
Journal: Current oncology (Toronto, Ont.)
Published: April 04, 2025
Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response?
Journal: The Annals of thoracic surgery
Published: March 31, 2025
Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study).
Journal: Current oncology (Toronto, Ont.)
Published: December 13, 2024
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 08, 2024
CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC.
Journal: JTO clinical and research reports
Published: June 13, 2024
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Journal: Lancet (London, England)
Published: May 30, 2023
Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases.
Journal: Neuro-oncology advances
Published: April 07, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 21, 2022
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Journal: Cancer treatment and research communications
Published: September 25, 2022
Last Updated: 09/26/2026